Pfizer Inc. (NYSE:PFE) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lowered its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 14.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 139,990,889 shares of the biopharmaceutical company's stock after selling 23,736,431 shares during the period. Pfizer accounts for 0.7% of Wellington Management Group LLP's investment portfolio, making the stock its 25th biggest position. Wellington Management Group LLP owned about 2.47% of Pfizer worth $3,713,958,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer during the 4th quarter worth $28,000. Noble Wealth Management PBC purchased a new position in shares of Pfizer in the 4th quarter worth $31,000. Finally, Curio Wealth LLC purchased a new position in shares of Pfizer in the 4th quarter worth $32,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Pfizer stock traded down $0.82 during mid-day trading on Tuesday, reaching $24.53. The company's stock had a trading volume of 54,333,514 shares, compared to its average volume of 39,155,822. The firm has a market cap of $139.09 billion, a price-to-earnings ratio of 17.39, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The business has a 50 day moving average price of $26.05 and a 200-day moving average price of $26.88. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research analyst reports. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup lowered their price target on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Finally, Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $31.92.

Insider Activity

In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.06% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.